|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
5115
|
Provisional Schedule
| Committee meeting |
06 August 2024 |
| Expected publication |
16 October 2024 |
Project Team
| Project lead |
Louise Jafferally |
Email enquiries
| External Assessment Group |
School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
| Companies sponsors |
Bristol-Myers Squibb (fedratinib) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Blood Cancer UK |
| |
Leukaemia Care |
| |
MPN Voice |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Associated public health groups |
None |
| Comparator companies |
GlaxoSmithKline (momelotinib) (confidentiality agreement signed, participating) |
| |
Novartis (ruxolitinib) (confidentiality agreement signed, participating) |
| |
Masters Pharmaceuticals (hydroxycarbamide) (confidentiality agreement not signed, not participating) |
| |
Medac UK (hydroxycarbamide) (confidentiality agreement not signed, not participating) |
| |
Neon Healthcare Ltd (hydroxycarbamide) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
08 January 2024
|
Invitation to participate |
|
20 October 2023
|
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early January 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
|
11 September 2023 - 02 October 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
04 July 2023
|
In progress. Topic in appraisal. |
For further information on our processes and methods, please see our CHTE processes and methods manual